Lutonix

company

About

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$20M
Industries
Biotechnology,Health Care,Medical Device
Founded date
Jan 1, 2007
Number Of Employee
11 - 50
Operating Status
Active

Lutonix DCB is a new drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation. Paclitaxel is an anti-proliferative drug commonly used to prevent arterial restenosis.

Lutonix DCB is very similar to a standard angioplasty balloon, but contains a special coating consisting of paclitaxel and a proprietary carrier that facilitates the drug’s transfer to the arterial wall upon inflation. This highly efficient formulation allows Lutonix DCB to deliver a therapeutic dose to the artery wall, while keeping the dose of paclitaxel on the balloon as low as possible. A lower balloon drug load minimizes systemic drug exposure and is designed to maximize safety.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Lutonix has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Oct 1, 2008 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 1, 2008 Series B $20M 1 Versant Ventures Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Lutonix is funded by 1 investors. Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Versant Ventures Yes Series B